Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2007-10-23
2007-10-23
Helms, Larry R. (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S387300
Reexamination Certificate
active
10830956
ABSTRACT:
The present invention provides chimeric and humanized antibodies that specifically recognize α5β1 integrin, and methods for using the antibodies for reducing or inhibiting angiogenesis in a tissue. Also provided are methods of determining therapeutically acceptable doses of the antibodies and pharmaceutical compositions including the same.
REFERENCES:
patent: 4704366 (1987-11-01), Juarez-Salinas et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5677181 (1997-10-01), Parish
patent: 5874081 (1999-02-01), Parish
patent: 6123941 (2000-09-01), Bissell et al.
patent: 6852318 (2005-02-01), Varner
patent: 2002/0172675 (2002-11-01), Varner
patent: 2004/0259152 (2004-12-01), Murray et al.
patent: WO 2001/53262 (2001-07-01), None
patent: WO 2001/53297 (2001-07-01), None
Wong et al. (Current Eye Research 22(2):140-147 (2001).
Sequence search alignment for SEQ ID Nos. 1 and 7 (pp. 1-2).
Zhao et al. (J. Cell Biol. 152(9):65-71 (Jan. 8, 2001).
Amit et al. Science 233: 747-753, 1986.
Vajdos et al. (J. Molec. Biol. (2002) 320, 415-428).
Wu et al. (J. Mol. Biol. (1999) 294, 151-162).
Valera Pharmaceuticals, Press Release: Hydron Implant technology (p. 1).
Valera Pharmaceuticals, Technology Release: Hydron Implant technology (p. 1).
PCT/US2004/010422 International search report, Feb. 8, 2005, PCT.
Varner, et. al., “Antagonist of Vascular Cell Integrin Alpha5beta1 Inhibit Angiogenesis”Circulation, American Heart Association, 98(17):abstract (1998).
Wu, H., et. al., “The Expression Of Integrin Alph5beta1 And Transforming Growth Factor-Beta In Pulmonary Fibrosis Of Rat”Chinese Journal of Pathology, 28(6): abstract (1999).
Zhao, Ming Wei et. al., A Distinct Integrin-Mediated Phagocytic Pathway For Extracellular Matrix Remodeling by RPE Cells:Invest. Opthalmol. Vis. Sci., 40(11):2713-2723 (1999).
Wilson, Sylvia et. et al., “Fibronectin Fragments Promote Human Retinal Endothelial Cell Adhesion and Proliferation and ERK Activation Through Alph5beta1 Integrin and PI 3-Kinase”Invest. Ophthalmol. Vis. Sci., 44(4):1704-1715 (2003).
Loike, J.D. et. al., “Blockade Of Alpa 5 Beta 1 Integrins Reverses The Inhibitory Effect Of Tenacin On Chemotaxis Of Human Monocytes And Polymorphonuclear Leukocytes Through Three-Dimensional Gels Of Extracellular Matrix Proteins”Journal of Immunology166(12):7534-7542 2001.
Kim, Semi et. al., “Regulation Of Integrin Alpha5beta3-Mediated Endothelial Cell Migration And Angiogenesis By Integrin Alpha5beta1 And Protein Kinase A”Journal of Biological Chemistry, 275(43):33920-33928 (2000).
Tolentino, Michael, J., et. al., “Angiography Of Fluoresceinated Anti-Vascular Endothelial Growth Factor Antibody And Dextrans In Experimental Choroidal Neovascularization”Archives of Ophthalmology, 118(1):78-84 (2000).
Ryan, S.J., “The Development Of An Experimental Model Of Subretinal Neovascularization In The Disciform Macular Degeneration”Transactions of the American Ophthalmological Society77:707-745, (1979).
Grossniklaus, Hans et. al., “Immunohistochemical And Histochemcial Properties Of Surgically Excised Subretinal Neovascular Membranes In Age-Related Macular Degeneration”American Journal of Ophthalmology114(4):464-472 (1992).
International Search Report dated Jul. 8, 2005.
Edelman and Castro, “Quantitative Image Analysis of Laser-Induced Choroidal Neovascularization in Rat,”Exp. Eye Res, 71:523-533 (2000).
Conforti, et al., “Human endothelial cells express integrin receptors on the luminal aspect of their membrane,”Blood, 80(2):437-446 (1992).
Storgard, Chris M. et al., “Decreased Angiogenesis and Arthritic Disease in rabbits Treated with an αvβ3 Antagonist”,The Journal of clinical Investigation, vol. 103 (1999), pp. 47-54.
Jeffry Ursula
Johnson Dale E.
Powers David
Ramakrishnan Vanitha
Biro Michael
Bristol Lynn
Helms Larry R.
Howrey LLP
PDL Biopharma, Inc.
LandOfFree
Chimeric and humanized antibodies to α5β1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric and humanized antibodies to α5β1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric and humanized antibodies to α5β1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3830317